Clinical Trial Update: A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating atrasentan in men with metastatic, hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: Abbott | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED